The Relationship of Comorbid Diseases and Empirical Antibiotic Usage with Superinfection in COVID-19 Patients.

IF 0.7 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL
Filiz Orak, Selcuk Nazik, Kezban Tulay Yalcinkaya, Murat Aral, Selma Ates, Adem Doganer
{"title":"The Relationship of Comorbid Diseases and Empirical Antibiotic Usage with Superinfection in COVID-19 Patients.","authors":"Filiz Orak,&nbsp;Selcuk Nazik,&nbsp;Kezban Tulay Yalcinkaya,&nbsp;Murat Aral,&nbsp;Selma Ates,&nbsp;Adem Doganer","doi":"10.29271/jcpsp.2023.08.852","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To identify the microorganisms responsible for superinfections in patients admitted with COVID-19 and evaluate the impact of empirical antibiotic regimen and comorbid disease on superinfections comparing COVID-19 patients with and without secondary infection.</p><p><strong>Study design: </strong>A descriptive study. Place and Duration of the Study: Department of Microbiology, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkiye, from March to July 2020.</p><p><strong>Methodology: </strong>This study was conducted with patients diagnosed with COVID-19 disease based on radiological or quantitative RT-PCR test results. Culture results, demographic characteristics, clinical variables, and therapeutic regimen were collected from medical records.</p><p><strong>Results: </strong>Superinfection developed in 48 (26.96%) of 178 cultures (24 of 101 patients) followed up in the COVID-19 clinics. Infections were determined as 25 (52.08%) bloodstream, 11 (22.9%) urinary tract, 10 (20.8%) respiratory tract and 2 (4.16%) soft tissue infections, respectively. Secondary infectious agents were E.coli in 11 (22.9%), A.baumannii in 8 (16.7%), S.homminis in 7 (14.6%), S.epidermidis in 6 (12.5%), K.pneumoniae in 4 (8.3%), C.albicans in 2 (4.1%), and other bacterial and fungal agents in 10 (20.8%). The median range from admission to the hospital to detecting microorganism growth was the longest with piperacillin/tazobactam with moxifloxacin and azithromycin. Secondary microorganism detection was delayed, mostly due to the empirical use of moxifloxacin, azithromycin, and piperacillin/tazobactam.</p><p><strong>Conclusion: </strong>Demographic characteristics, comorbidity and antibiotic use of patients were not directly related to secondary infections. In addition, the empirical use of azithromycin and moxifloxacin with piperacillin/tazobactam appeared to delay the development of superinfection.</p><p><strong>Key words: </strong>Superinfection, COVID-19, Comorbidity.</p>","PeriodicalId":54905,"journal":{"name":"Jcpsp-Journal of the College of Physicians and Surgeons Pakistan","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jcpsp-Journal of the College of Physicians and Surgeons Pakistan","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.29271/jcpsp.2023.08.852","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To identify the microorganisms responsible for superinfections in patients admitted with COVID-19 and evaluate the impact of empirical antibiotic regimen and comorbid disease on superinfections comparing COVID-19 patients with and without secondary infection.

Study design: A descriptive study. Place and Duration of the Study: Department of Microbiology, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkiye, from March to July 2020.

Methodology: This study was conducted with patients diagnosed with COVID-19 disease based on radiological or quantitative RT-PCR test results. Culture results, demographic characteristics, clinical variables, and therapeutic regimen were collected from medical records.

Results: Superinfection developed in 48 (26.96%) of 178 cultures (24 of 101 patients) followed up in the COVID-19 clinics. Infections were determined as 25 (52.08%) bloodstream, 11 (22.9%) urinary tract, 10 (20.8%) respiratory tract and 2 (4.16%) soft tissue infections, respectively. Secondary infectious agents were E.coli in 11 (22.9%), A.baumannii in 8 (16.7%), S.homminis in 7 (14.6%), S.epidermidis in 6 (12.5%), K.pneumoniae in 4 (8.3%), C.albicans in 2 (4.1%), and other bacterial and fungal agents in 10 (20.8%). The median range from admission to the hospital to detecting microorganism growth was the longest with piperacillin/tazobactam with moxifloxacin and azithromycin. Secondary microorganism detection was delayed, mostly due to the empirical use of moxifloxacin, azithromycin, and piperacillin/tazobactam.

Conclusion: Demographic characteristics, comorbidity and antibiotic use of patients were not directly related to secondary infections. In addition, the empirical use of azithromycin and moxifloxacin with piperacillin/tazobactam appeared to delay the development of superinfection.

Key words: Superinfection, COVID-19, Comorbidity.

COVID-19患者合并症及经验性抗生素使用与重复感染的关系
目的:确定新冠肺炎住院患者中导致重复感染的微生物,并比较有无继发感染的新冠肺炎患者,评估经验性抗生素治疗方案和合并症对重复感染的影响。研究设计:描述性研究。研究地点和时间:2020年3月至7月,土耳其Kahramanmaras Sutcu伊玛目大学微生物学系。方法:本研究采用放射学或定量RT-PCR检测结果诊断为COVID-19疾病的患者。从医疗记录中收集培养结果、人口统计学特征、临床变量和治疗方案。结果:临床随访178例(101例患者中24例)培养物中48例(26.96%)发生重复感染。血流感染25例(52.08%),泌尿道感染11例(22.9%),呼吸道感染10例(20.8%),软组织感染2例(4.16%)。继发感染病原为大肠杆菌11例(22.9%),鲍曼假单胞菌8例(16.7%),人型假单胞菌7例(14.6%),表皮假单胞菌6例(12.5%),肺炎克雷伯菌4例(8.3%),白色假单胞菌2例(4.1%),其他细菌和真菌10例(20.8%)。哌拉西林/他唑巴坦组、莫西沙星和阿奇霉素组从入院到检测微生物生长的中位时间最长。二次微生物检测延迟,主要是由于经验性使用莫西沙星、阿奇霉素、哌拉西林/他唑巴坦。结论:患者的人口学特征、合并症和抗生素使用与继发感染无直接关系。此外,阿奇霉素和莫西沙星与哌拉西林/他唑巴坦联合使用的经验似乎可以延缓重复感染的发生。关键词:重复感染;COVID-19;合并症
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
0.00%
发文量
453
审稿时长
3-6 weeks
期刊介绍: Journal of College of Physicians and Surgeons Pakistan (JCPSP), is the prestigious, peer reviewed monthly biomedical journal of the country published regularly since 1991. Established with the primary aim of promotion and dissemination of medical research and contributed by scholars of biomedical sciences from Pakistan and abroad, it carries original research papers, , case reports, review articles, articles on medical education, commentaries, short communication, new technology, editorials and letters to the editor. It covers the core biomedical health science subjects, basic medical sciences and emerging community problems, prepared in accordance with the “Uniform requirements for submission to bio-medical journals” laid down by International Committee of Medical Journals Editors (ICMJE). All publications of JCPSP are peer reviewed by subject specialists from Pakistan and locally and abroad.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信